Guidance

Psychotropic drugs and people with learning disabilities or autism

Describes a system to track prescribing of antipsychotics, antidepressants and other psychotropics for people with learning disabilities, autism or both.

From:
Public Health England
Published
22 March 2019

Documents

Psychotropic drugs and people with learning disabilities or autism: executive summary

Ref: PHE publication gateway reference: GW-103

HTML

Psychotropic drugs and people with learning disabilities or autism: introduction

Ref: PHE publications gateway number: GW-103

HTML

Psychotropic drugs and people with learning disabilities or autism: methods

Ref: PHE publication gateway reference: GW-103

HTML

Psychotropic drugs and people with learning disabilities or autism: results

Ref: PHE publication gateway reference: GW-103

HTML

Psychotropic drugs and people with learning disabilities or autism: discussion

Ref: PHE publication gateway reference: GW-103

HTML

Psychotropic drugs and people with learning disabilities or autism: annexes

Ref: PHE publications gateway number: GW-103

PDF, 125 KB, 6 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Psychotropic drugs and people with learning disabilities or autism: code lists

Ref: PHE publications gateway number: GW-103

PDF, 1.09 MB, 78 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Psychotropic drugs and people with learning disabilities or autism: easy-read summary

Ref: PHE publications gateway number: GW-103

PDF, 292 KB, 5 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This study was commissioned by NHS England to devise a method to report the impact of their programme to stop overmedication for people with learning disabilities, autism or both (STOMP). It provides data about the extent and trends in the use of psychotropic drugs between January 2010 and December 2017.

The methods used in this study could be used to monitor the trends in prescribing rates and patterns of psychotropic drugs prescribed by GPs for people with learning disabilities, autism or both.

The conclusions from the study were limited due to the short period of time and a reducing population coverage towards the end of the time period studied. Other similar data sources are available and the methods used in this study could be applied to them.

Even with the limited data points, the study showed that, following the launch of STOMP, changes to GP prescribing of psychotropic drugs were beginning to happen in the desired direction for adults with learning disabilities.

Published 22 March 2019

Related content